Men who carry germline variants in BRCA2 with metastatic disease have been shown to have superior responses to PARP inhibition and platinum chemotherapy, signalling the emerging importance of knowing a patient’s variant status, especially if presenting with advanced or metastatic disease [23–25]. Here, BRCA2 is linked to metastatic neoplasm.